Background/aim-Inactivation of the p16 INK4A (p16) tumour suppressor gene by promoter region hypermethylation has been demonstrated not only in many types of tumours, including hepatocellular carcinoma (HCC), but also in early preneoplastic lesions in the lung, colon, oesophagus, and pancreas. The aim of this study was to examine the methylation status of the p16 promoter in pre-and/or non-neoplastic liver diseases. Patients/subjects/methods-The methylation status of p16 was evaluated in 22 HCC, 17 cirrhosis, 17 chronic hepatitis, nine primary biliary cirrhosis (PBC), eight autoimmune hepatitis, seven drug induced liver disease, six fatty liver, and three normal liver tissues using methylation specific polymerase chain reaction (MSP). p16 protein expression was also examined by immunohistochemical staining. 
Hepatocellular carcinoma (HCC) is one of the most common malignancies in the world and one of the leading causes of cancer death in Japan. 1 Hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infections are thought to be involved in hepatocarcinogenesis. Chronic hepatitis and cirrhosis associated with either HBV or HCV precede most HCCs. The process of chronic inflammation and cirrhosis is often accompanied by regeneration of hepatocytes, and the continuous regeneration may predispose hepatocytes to uncontrolled growth and malignant transformation as a result of disruption of cell cycle regulation, senescence, and apoptosis. HBV encodes a gene product that can interact with p53 and impair the physiological function of p53. 2 The core protein of HCV has been shown to modulate gene transcription, cell proliferation, and cell death. 3 4 However, the mechanisms underlying virus associated hepatocarcinogenesis are still unclear.
p16, a cyclin dependent kinase inhibitor, plays an important role in cell cycle regulation 5 and senescence. 6 p16 is one of the most frequently altered tumour suppressor genes in human cancer. 7 Frequent loss of p16 expression has been reported in HCC. 8 However, mutations and homozygous deletions of p16 have been shown to be rare in HCC, [8] [9] [10] [11] [12] [13] [14] although conflicting results have been reported. 15 16 The reported LOH at 9p21, on which p16 gene is located, also shows varying frequencies in HCC. 9-13 15 The discrepancies in the reported frequencies in p16 alterations may be due to diVerences in risk factors, such as HBV, HCV, and alcohol, and diVerences in geographic regions.
It has been proposed that aberrant methylation of CpG islands, which are CpG dinucleotide rich areas located mainly in the promoter regions of many genes, serves as an alternative mechanism for inactivation of the tumour suppressor gene in cancer. 17 18 In contrast with the infrequent genetic alterations, frequent methylation of the p16 promoter has been observed in HCC, 11 13 14 19 although one study failed to detect methylation in HCC. 20 The discrepancy can be explained by the fact that samples with diVerent ethnic and aetiological backgrounds were analysed and/or that diVerent methods were used. The discrepancy may result from diVerent proportions of specific aetiologies, such as HBV and HCV infections, in the studies.
Recently, aberrant methylation of the p16 promoter has also been reported in early preneoplastic lesions in the lung, 21 colon, 22 oesophagus, 23 and pancreas. 24 These findings suggest that loss of p16 function, often due to promoter methylation, may be an early event in the pathogenesis of various types of tumours. 25 In this regard, it is of interest that weak amplification of methylated DNA has been seen in a small number of non-tumour liver tissues in which strong signals of methylated DNA were detected in the corresponding tumour tissues. 13 Although these findings suggest that de novo methylation of the p16 promoter could occur in premalignant or early subcellular malignant changes in hepatocarcinogenesis, the functional significance of these observations has not been elucidated. In this study, we analysed 5' CpG island methylation of p16 and correlated the results with immunohistochemical expression of p16 protein in 89 specimens from HCCs, pre-and/or non-neoplastic liver diseases, with or without hepatitis virus infections, and normal livers. The principles of the method have been described previously. 25 In the chemical modification of cytosine to uracil by bisulphite treatment, all cytosines are converted to uracil, but those that are methylated are resistant to this modification and remain as cytosine. One can design polymerase chain reaction (PCR) primers to distinguish methylated from unmethylated DNA in bisulphite modified DNA, taking advantage of the sequence diVerences resulting from bisulphite modification. 25 Genomic DNA (2 µg) extracted from frozen tissues by the standard phenol/chloroform procedure was denatured in 0.2 M NaOH for 15 minutes. Sodium bisulphite (Sigma Chemical, St Louis, Missouri, USA) was added to a final concentration of 3.1 M, and hydroquinone (Sigma Chemical) was added to a final concentration of 0.5 mM. The reaction was performed at 50°C for 16 hours. Modified DNA was then purified using Wizard DNA purification resin (Promega, Madison, Wisconsin, USA) according to the manufacturer's protocol and eluted with 50 µl of water. DNA was treated with NaOH (final concentration 0.3 M) for five minutes at room temperature, followed by ethanol precipitation. Modified DNA was resuspended in water and used immediately or stored at −20°C.
Materials and methods

TISSUE
Figure 1 Methylation specific polymerase chain reaction (PCR) analysis and expression of p16 gene. (A) Hepatocellular carcinoma (HCC) samples. (B) Liver cirrhosis (LC) and chronic hepatitis (CH) samples. (C) Primary biliary cirrhosis (PBC), autoimmune hepatitis (AIH), drug induced liver disease (DLD), fatty liver (FL), and normal liver (NL) samples. Unmethylated and methylated indicate methylation specific PCR analysis specific for unmethylated and methylated promoter of p16, respectively. (+), normal expression of p16; (±), partial loss of p16 expression; (−), complete loss of p16 expression.
METHYLATION SPECIFIC PCR (MSP)
Bisulphite modified DNA was subjected to MSP using primers specific for unmethylated p16 (5'-TTATTAGAGGGTGGGGTGGAT TGT-3' and 5'-CAACCCCAAACCACAAC CATAA-3') or methylated p16 (5'-TTAT TAGAGGGTGGGGCGGATCGC-3' and 5' -GACCCCGAACCGCGACCGTAA-3'). 25 PCR reactions were performed in a volume of 50 µl containing 1×PCR buVer, 0.25 mM dNTP, 1 mM of each primer, and 2.5 U of Taq polymerase. PCR conditions were as follows: one cycle of 95°C for five minutes; 35 cycles of 95°C for 30 seconds, 60°C (unmethylated) or 65°C (methylated) for 30 seconds, and 72°C for 30 seconds; and one cycle of 72°C for four minutes. 25 PCR samples were then electrophoresed on a 3% agarose gel.
IMMUNOHISTOCHEMISTRY
Tissue sections (4-5 µm) were deparaYnised and incubated in target retrieval solution (Dako, Carpinteria, California, USA) at the recommended dilution and heated by steam for 15 minutes. Slides were incubated overnight at 4°C with a mouse monoclonal anti-p16 antibody (Neomarkers, Union City, California, USA) diluted to a final concentration of 4 µg/ml. Negative control slides were treated with normal rabbit immunoglobulin under similar conditions. Slides were then rinsed with phosphate buVered saline and incubated with the secondary antibody using the Dako LSAB 2 System (Dako), developed with diaminobenzidine (Kanto Chemical, Tokyo) for five minutes, and counterstained with haematoxylin for one minute.
STATISTICAL ANALYSIS
Methylation of the p16 promoter was assessed for associations with clinicopathological characteristics using the 2 fig 1B, fig 2,  table 1 ). In contrast, none of the nine PBC, eight autoimmune hepatitis, seven drug induced liver disease, six fatty liver, or three normal liver tissues showed p16 promoter methylation ( fig 1C, fig 2) . All methylation positive tissue samples were positive for either HBV or HCV (fig 2, table 1 ). Positivity for p16 promoter methylation was not diVerent between HBV and HCV positive patients in HCC (7/9 v 9/13), cirrhosis (2/7 v 3/10), or chronic hepatitis (1/7 v 3/10). Unmethylated bands were also detected in all methylation positive cases ( fig 1A, 1B) . There was no significant correlation between methylation of the p16 promoter and age, type of viral infection, tumour cell diVerentiation, tumour size, or histological findings in HCC (table 1) . 1B) . One complete 
Discussion
In this study, we analysed the methylation status of the 5' CpG island of the p16 gene promoter in a series of HCC and pre-and/or non-neoplastic liver diseases with or without hepatitis virus infections. Methylation of the p16 promoter was detected in 72.7% of HCCs, 29.4% of cirrhosis, and 23.5% of chronic hepatitis tissues, all of which were positive for HBV or HCV infections. In contrast, methylation was not detected in any of the tissue samples from non-viral liver diseases, including PBC, autoimmune hepatitis, drug induced liver disease, and fatty liver, suggesting that this epigenetic change may be related to hepatitis virus infections.
All of the HCC, cirrhosis, and chronic hepatitis samples with promoter methylation showed loss of expression, and a significant correlation between methylation and loss of 
Figure 3 Immunohistochemistry of p16 using the mouse anti-p16 monoclonal antibody. Strong nuclear immunostaining was detected in normal liver (A), fatty liver (B), drug induced liver disease (C), autoimmune hepatitis (D), and primary biliary cirrhosis (E) samples. (F) and (G) Partial loss of p16 expression in chronic hepatitis samples. Complete loss of p16 expression in cirrhosis (H) and hepatocellular carcinoma (I) samples.
expression was observed. Therefore, methylation of the p16 promoter detected in this study appears to have a functional significance. Furthermore, it is notable that the majority of patients with methylation positive HCC had loss of p16 expression with promoter methylation at the stage of chronic hepatitis without clinically detectable carcinoma. Our results suggest that methylation of the p16 promoter is one of the earliest events in a subset of hepatitis virus associated hepatocarcinogenesis. Our results are consistent with the findings of several recent studies indicating that inactivation of p16 by hypermethylation is an early event in cancer development of the lung, 21 colon, 22 oesophagus, 23 and pancreas. 24 Thus our results confirm recently reported observations of frequent methylation of the p16 promoter in HCC and extend the observations to chronic liver diseases associated with hepatitis virus infections. Further analysis, including a number of non-virus associated cases, is required to clarify the possible intriguing relationship between methylation of the p16 promoter and chronic hepatitis virus infections.
In all of the methylation positive cases, unmethylated bands were also detected. One possible explanation is that these unmethylated bands were due to contaminated normal tissues in the tumour, such as inflammatory cells and normal liver cells. Considering the loss of expression, both alleles appear to be inactivated by biallelic methylation or methylation in conjunction with genetic alterations, such as mutation, LOH, and homozygous deletion, as shown in a previous study. 13 Several HCC, cirrhosis, and chronic hepatitis samples without methylation also showed loss of p16 expression, suggesting that the above mentioned genetic alterations play a role in inactivation of the p16 gene. In contrast with our results, several previous studies have failed to detect methylation of the p16 promoter in chronic non-tumour liver diseases, including those of viral origin. 11 14 These conflicting observations may be due to diVerences in the methods for detection of methylation and/or in the ethnic and aetiological backgrounds of individuals. However, these factors in our study were similar to those in the study of Matsuda and colleagues.
14 Nevertheless, our observation is unlikely to be simply overestimation of methylation as we found a good correlation between methylation and loss of expression.
All methylation positive HCC showed complete loss of p16 expression while the majority of methylation positive cirrhosis and chronic hepatitis samples showed partial loss of expression. It has been suggested that accumulation of methylated cytosine in the 5' CpG island of p16 may silence this gene in a dose dependent manner. 26 It has been reported that partial loss of p16 expression was associated with lower levels of methylation than complete loss, suggesting that methylation, and loss of expression, of p16 occurs in a progressive manner. 14 27 Gradual loss of p16 expression associated with progressive p16 promoter methylation has also been reported in the escape of mammary epithelial cells from senescence. 28 Therefore, partial loss of p16 expression in cirrhosis and chronic hepatitis may be due to the heterogeneity of methylation in hepatocytes, and the population of cells with methylated alleles may increase during progression to HCC. It seems intriguing to speculate that cells with loss of p16 expression are more likely to progress to tumorous cells than are those with normal p16 function.
The precise mechanisms leading to aberrant methylation of CpG islands in neoplastic cells are not known. Moreover, little is known of the link between viral infections and methylation machinery. Recently, human immunodeficiency virus has been shown to induce methylation of interferon through increased DNA methyltransferase activity. 29 Interestingly, Sun et al have reported increased levels of DNA methyltransferase mRNA in liver tissues from chronic hepatitis and cirrhosis compared with those in normal liver tissues. 30 However, several lines of experimental evidence suggest that there is no correlation between DNA methyltransferase activity and aberrant methylation of endogenous genes. 31 Therefore,aberrant methylation of the p16 promoter may not be caused directly by elevated DNA methyltransferase activity in hepatocarcinogenesis. Other mechanisms such as loss of protection against de novo methylation may underlie aberrant methylation of p16 during hepatocarcinogenesis. 17 18 Our results warrant further investigation.
Although further study is necessary to clarify the link between hepatitis virus infections and methylation of p16 in hepatocarcinogenesis, detection of p16 promoter methylation could be a useful molecular marker to follow up patients with a high risk of developing HCC, such as those with HBV or HCV infections. It would be of interest to prospectively examine whether patients with p16 methylation positive cirrhosis or chronic hepatitis have a higher risk of developing HCC compared with those without p16 methylation.
